BP to Sell $4 Billion US Biogas Unit as Profit Surge Funds Portfolio Rationalization

The Quick Take

• BP announced plans to sell its US biogas business for approximately $4 billion amid a reported profit surge
• The divestiture continues BP's portfolio restructuring programme, redirecting capital away from non-core renewable assets
• Sale of biogas assets follows a pattern of energy majors monetising clean-energy positions during elevated fossil-fuel profit cycles

BP's announcement of a planned $4 billion sale of its US biogas business arrives alongside a reported profit surge, marking the latest move in a multi-year portfolio restructuring by one of the world's largest integrated energy companies. The biogas divestiture continues BP's pattern of selling non-core or lower-return renewable assets as elevated oil and gas profits improve the attractiveness of redirecting capital into upstream projects with higher near-term returns. BP, which aggressively expanded into bioenergy, offshore wind, and carbon capture under its Beyond Petroleum rebranding, has progressively scaled back those commitments as shareholder pressure for near-term returns has intensified across the energy major complex.

A $4 billion biogas sale will draw interest from utilities, independent power producers, and infrastructure funds seeking stable long-duration cash flows from biomethane assets. Peer energy majors — Shell, TotalEnergies, and Equinor — are monitoring BP's divestiture as a price-discovery event for US biogas infrastructure, which benefits from the US EPA's Renewable Fuel Standard credit mechanism. For investors in the US gas sector, the sale signals that institutional pricing of biogas infrastructure remains healthy despite BP's strategic retreat, and pipeline operators or renewable gas processors are the most natural buyer profiles given their existing distribution infrastructure.

Forward signals include BP's next quarterly earnings call, where management is expected to provide detail on the divestiture timeline, buyer shortlist, and anticipated net proceeds. The macro variable is the US Renewable Fuel Standard D3 RIN credit price — elevated RIN credits support biogas asset valuations and buyer appetite; any regulatory change to the RFS programme would materially affect sale pricing. BP's own balance sheet trajectory is the secondary watch: if profits continue to surge, the urgency to complete the sale may decrease, potentially allowing BP to negotiate premium terms or delay into a higher-liquidity market window.

Synthesized from 1 source.